Bruker Corporation (NASDAQ:BRKR) Receives $54.54 Consensus Price Target from Brokerages

Shares of Bruker Corporation (NASDAQ:BRKR) have received an average rating of “Hold” from the sixteen brokerages that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, six have given a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $55.6429.

Several analysts have recently weighed in on the company. Stifel Nicolaus set a $45.00 target price on Bruker in a research report on Friday, May 8th. Barclays lifted their price objective on shares of Bruker from $53.00 to $60.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. Weiss Ratings raised shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, June 3rd. Wall Street Zen raised shares of Bruker from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, UBS Group set a $60.00 price target on Bruker in a report on Wednesday, June 24th.

Insider Activity at Bruker

In related news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total value of $79,800.00. Following the completion of the sale, the vice president directly owned 128,443 shares in the company, valued at $5,124,875.70. The trade was a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 27.20% of the company’s stock.

Hedge Funds Weigh In On Bruker

A number of large investors have recently bought and sold shares of BRKR. Orbis Allan Gray Ltd bought a new stake in shares of Bruker in the 2nd quarter valued at about $192,735,000. Price T Rowe Associates Inc. MD lifted its position in Bruker by 2,963.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company’s stock valued at $111,488,000 after acquiring an additional 2,289,269 shares during the last quarter. AQR Capital Management LLC boosted its stake in Bruker by 125.3% in the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after acquiring an additional 1,850,215 shares in the last quarter. Franklin Resources Inc. grew its holdings in Bruker by 317.7% in the fourth quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock worth $108,796,000 after purchasing an additional 1,756,460 shares during the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of Bruker by 222.6% during the 4th quarter. Millennium Management LLC now owns 1,839,587 shares of the medical research company’s stock valued at $86,663,000 after purchasing an additional 1,269,316 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.

Bruker Price Performance

BRKR stock opened at $58.25 on Wednesday. The stock has a market cap of $8.87 billion, a PE ratio of -242.71, a P/E/G ratio of 1.96 and a beta of 1.29. Bruker has a 12 month low of $28.53 and a 12 month high of $64.54. The company has a 50-day moving average price of $51.50 and a 200 day moving average price of $45.23. The company has a current ratio of 1.55, a quick ratio of 0.72 and a debt-to-equity ratio of 0.67.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The business had revenue of $823.40 million during the quarter, compared to the consensus estimate of $795.62 million. During the same quarter last year, the firm earned $0.47 earnings per share. The firm’s quarterly revenue was up 2.7% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities research analysts anticipate that Bruker will post 2.12 earnings per share for the current year.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd were given a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, June 22nd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Bruker’s dividend payout ratio is presently -83.33%.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.